ZVRA Zevra Therapeutics, Inc.

$12.54 +1.87%

Updated 16 d ago

Healthcare · Pharmaceutical Preparations

Zevra Therapeutics, Inc. (ZVRA) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $745 million. Shares last traded at $12.54, 16.6% below their 52-week high. Over the past year the stock is up 40.7%. ZVRA trades at a price-to-earnings ratio of 12.78, below the Pharmaceutical Preparations median of 17.31. Net profit margin is 42.8%, above the peer median of -8.9%. Revenue grew 350.9% year over year.

Market Cap

$745M

Shares Out

59.4M

EPS (TTM)

$3.66

P/E Ratio

3.43

P/S Ratio

5.47

P/B Ratio

3.42

Dividend / Share

—

Dividend Yield

—

52-Week High

$15.04

52-Week Low

$7.16

Volume

33,930

Avg Vol (3m)

78,541.254

Performance

+5.91%

+18.98%

+12.16%

+42.82%

YTD

+50.27%

+40.74%

Chart

Full chart →

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)

60.23

SMA (50)

$12.05

SMA (200)

$10.28

Price vs SMA50

+4.10%

Price vs SMA200

+22.01%

ATR (14)

$0.47

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue

$136M

Net Income

$58M

Gross Margin

—

Operating Margin

60.5%

Net Margin

42.8%

Return on Equity

26.8%

Return on Assets

19.2%

Current Ratio

5.17

Debt / Equity

0.00

Revenue Growth (YoY)

+350.9%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

Period	EPS (diluted)	Reported
Q2 2026	$0.74	2026-08-05
Q1 2026	$0.60	2026-05-06
FY 2025	$1.35	2026-03-09
Q3 2025	$1.16	2025-11-05
Q2 2026	$1.16	2026-08-05
Q1 2026	$-0.06	2026-05-06

Full earnings history →

Pharmaceutical Preparations peers

ZVRA vs 14 industry peers (Pharmaceutical Preparations), by market cap. Updated 16 d ago

P/E vs peers

12.78 / 17.31 med

-26% discount

P/S vs peers

5.47 / 11.11 med

-51% discount

Net margin vs peers

42.8% / -8.9% med

above median

1–14 of 14


LLY	Lilly (Eli)	$1.09T	40.86	13.70	33.5%	-0.02%
JNJ	Johnson & Johnson	$670.6B	31.88	6.85	21.5%	+1.04%
ONC	Beone Medicines Ltd.	$535.9B	817.25	87.43	10.7%	+0.23%
ABBV	AbbVie	$459.8B	72.87	7.14	9.8%	-0.57%
MRK	Merck	$375.8B	118.44	5.65	4.8%	+0.44%
ABT	Abbott Laboratories	$189.5B	30.20	4.20	13.9%	-1.50%
PFE	Pfizer	$164.2B	37.91	2.58	6.8%	-0.76%
VRTX	Vertex Pharmaceuticals	$141.5B	32.11	11.24	35.0%	+0.24%
BMY	Bristol Myers Squibb	$139.1B	14.98	2.83	18.9%	+0.62%
REGN	Regeneron Pharmaceuticals	$87.2B	20.15	5.61	27.9%	-1.02%
TEVA	Teva Pharmaceutical Industries Ltd	$42.6B	60.41	2.46	4.1%	-2.32%
ALNY	Alnylam Pharmaceuticals	$35.4B	43.77	9.52	21.8%	-1.10%
ZTS	Zoetis	$31.5B	12.05	3.31	27.5%	+0.16%
RPRX	Royalty Pharma Plc	$28.2B	34.56	11.11	32.1%	+1.24%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.